The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study

Sponsor
Sun Yat-sen University
Study ID
NCT07272265
Status
Completed

Conditions

  • Hepatocellular Carcinoma (HCC)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Atezolizumab & Bevacizumab — DRUG
    Atezolizumab 1200mg \& Bevacizumab 15mg/kg Q3W
  • FOLFOX-HAIC — PROCEDURE
    hepatic artery infusion chemotherapy of oxaliplatin, leucovorin, and fluorouracil

Study Details

This is a multicenter，retrospective study to explore the effectiveness and safety of Atezo/Bev plus hepatic artery infusion chemotherapy (HAIC) among adult patients with high-risk HCC in real-world clinical practice in China. Eligible patients diagnosed with high-risk HCC initiating the study treatment of interest between 28 October 2020 and 31 June 2025 will be included in this study. Secondary data from medical records of approximately 10 sites across China will be utilized.

Key Dates

Start date
Oct 28, 2020
Status verified
Nov 2025
Primary completion
May 31, 2025
Completion
Nov 10, 2025

Study Design

Enrollment
300 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: FOLFOX+TA
    FOLOFOX-HAIC plus Atezolizumab and Bevacizumab

Primary Outcome Measure

overall survival (OS) [ Time Frame: 6 months ]

Related Studies